Cardlytics, Inc. Files Definitive Proxy Statement (DEF 14A)

Ticker: CDLX · Form: DEF 14A · Filed: Apr 12, 2024 · CIK: 1666071

Cardlytics, Inc. DEF 14A Filing Summary
FieldDetail
CompanyCardlytics, Inc. (CDLX)
Form TypeDEF 14A
Filed DateApr 12, 2024
Risk Level
Pages17
Reading Time20 min
Sentimentneutral

Sentiment: neutral

Topics: Cardlytics, CDLX, DEF 14A, Proxy Statement, Executive Compensation

TL;DR

<b>Cardlytics, Inc. has filed its Definitive Proxy Statement (DEF 14A) for the 2023 fiscal year, detailing executive compensation and equity awards.</b>

AI Summary

Cardlytics, Inc. (CDLX) filed a Proxy Statement (DEF 14A) with the SEC on April 12, 2024. Cardlytics, Inc. filed a DEF 14A form on April 12, 2024. The filing covers the period from January 1, 2023, to December 31, 2023. Key executive compensation data for Karim Temsamani and Lynne Laube is included. Information on equity awards granted and vested for 2023 is detailed. The company is incorporated in Delaware and headquartered in Atlanta, GA.

Why It Matters

For investors and stakeholders tracking Cardlytics, Inc., this filing contains several important signals. This filing provides shareholders with crucial information regarding executive compensation, including details on equity awards granted and vested, which can influence investor decisions. As a DEF 14A filing, it outlines proposals to be voted on at the shareholder meeting, giving investors a direct say in corporate governance matters.

Risk Assessment

Risk Level: — Cardlytics, Inc. shows moderate risk based on this filing. The filing is a routine DEF 14A, providing standard disclosure information without immediate financial performance indicators or significant strategic shifts.

Analyst Insight

Review the executive compensation details and shareholder proposals to understand potential impacts on corporate governance and shareholder value.

Executive Compensation

NameTitleTotal Compensation
Karim TemsamaniMember
Lynne LaubeMember

Key Numbers

  • 2024-04-12 — Filing Date (DEF 14A filing date)
  • 2023-12-31 — Fiscal Year End (Reporting period end date)
  • 2023-01-01 — Fiscal Year Start (Reporting period start date)

Key Players & Entities

  • Cardlytics, Inc. (company) — Filer
  • Karim Temsamani (person) — Executive
  • Lynne Laube (person) — Executive
  • 675 Ponce de Leon Avenue, NE, Suite 4100 (address) — Business and Mail Address
  • Atlanta, GA (address) — Business and Mail City/State
  • DE (jurisdiction) — State of Incorporation

FAQ

When did Cardlytics, Inc. file this DEF 14A?

Cardlytics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 12, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Cardlytics, Inc. (CDLX).

Where can I read the original DEF 14A filing from Cardlytics, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Cardlytics, Inc..

What are the key takeaways from Cardlytics, Inc.'s DEF 14A?

Cardlytics, Inc. filed this DEF 14A on April 12, 2024. Key takeaways: Cardlytics, Inc. filed a DEF 14A form on April 12, 2024.. The filing covers the period from January 1, 2023, to December 31, 2023.. Key executive compensation data for Karim Temsamani and Lynne Laube is included..

Is Cardlytics, Inc. a risky investment based on this filing?

Based on this DEF 14A, Cardlytics, Inc. presents a moderate-risk profile. The filing is a routine DEF 14A, providing standard disclosure information without immediate financial performance indicators or significant strategic shifts.

What should investors do after reading Cardlytics, Inc.'s DEF 14A?

Review the executive compensation details and shareholder proposals to understand potential impacts on corporate governance and shareholder value. The overall sentiment from this filing is neutral.

How does Cardlytics, Inc. compare to its industry peers?

Cardlytics operates in the advertising and marketing technology sector, focusing on loyalty programs and data analytics for financial institutions.

Are there regulatory concerns for Cardlytics, Inc.?

As a publicly traded company, Cardlytics is subject to SEC regulations, including the requirement to file proxy statements (DEF 14A) for shareholder meetings.

Industry Context

Cardlytics operates in the advertising and marketing technology sector, focusing on loyalty programs and data analytics for financial institutions.

Regulatory Implications

As a publicly traded company, Cardlytics is subject to SEC regulations, including the requirement to file proxy statements (DEF 14A) for shareholder meetings.

What Investors Should Do

  1. Analyze the reported equity awards for executives Karim Temsamani and Lynne Laube.
  2. Review any shareholder proposals or director nominations outlined in the filing.
  3. Note the fiscal year end and filing date for context on the reported information.

Key Dates

  • 2024-04-12: Filing of DEF 14A — Provides details on executive compensation and shareholder matters for the 2023 fiscal year.

Year-Over-Year Comparison

This is a DEF 14A filing, which typically provides information on executive compensation and corporate governance, rather than financial performance updates found in 10-K or 10-Q filings.

Filing Stats: 4,983 words · 20 min read · ~17 pages · Grade level 11.8 · Accepted 2024-04-12 16:09:38

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 43 PAY VS. PERFORMANCE 48 DIRECTOR COMPENSATION 55 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS 57

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 58 DELINQUENT SECTION 16(A) REPORTS 59 PROPOSAL NO. 3 - ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS 59 TRANSACTION OF OTHER BUSINESS 60 TRANSACTIONS WITH RELATED PERSONS 60 HOUSEHOLDING OF PROXY MATERIALS 62 OTHER MATTERS 63 PROXY CARD 64 APPENDIX - A 66 4 PROXY STATEMENT FOR THE 2023 ANNUAL MEETING OF STOCKHOLDERS To Be Held on May 23, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the Internet? Pursuant to rules adopted by the Securities and Exchange Commission ("SEC"), we have elected to provide access to our proxy materials over the Internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the "Notice") because the Board of Directors of Cardlytics, Inc. ("we," "our," "us," the "Company," or "Cardlytics") is soliciting your proxy to vote at the Annual Meeting, including at any adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the Internet or to request a printed copy may be found in the Notice. We intend to mail the Notice on or about April 12, 2024 to all stockholders of record entitled to vote at the Annual Meeting. How do I attend the Annual Meeting? The meeting will be held on Thursday, May 23, 2024 at 2:00 p.m. Eastern Time at the offices of the Company at 675 Ponce de Leon Ave. NE, Suite 4100, Atlanta, GA 30308. Information on how to vote in person at the Annual Meeting is discussed below. Who can vote at the Annual Meeting? Only stockholders of record at the close of business on March 26, 2024 will be entitled to vote at the Annual Meeting. On this record date, there were 48,173,73

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.